Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448754 · ClinicalTrials.gov registry record · Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform Study
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06448754 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06448754, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Ramucirumab
- DRUG Volrustomig
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Hangzhou
- Research Site - Jinan
- Research Site - Yantai
- Research Site - Zhengzhou
- Research Site - Bois-Guillaume
- Research Site - Caen
- Research Site - Créteil
- Research Site - Dijon
- Research Site - Montpellier
- Research Site - Batumi
- Research Site - Tbilisi
Colorado
- Research Site - Grand Junction
- Research Site - Wheat Ridge
California
- Research Site - Los Angeles
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Detroit
North Carolina
- Research Site - Chapel Hill
Washington
- Research Site - Tacoma
Quebec
- Research Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06448754
The ClinicalTrials.gov registry entry for NCT06448754 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06448754 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Colorado, California.
Frequently Asked Questions
What is clinical trial NCT06448754 about?
NCT06448754 is a clinical study titled "Volrustomig Priming Regimens Exploratory Phase II Platform Study". Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
What is the current status of trial NCT06448754?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-08-27. Estimated completion is 2027-07-30.
What conditions does trial NCT06448754 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06448754?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Ramucirumab (DRUG), Volrustomig (DRUG).
Who is sponsoring clinical trial NCT06448754?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06448754 being conducted?
This trial has 20 study locations across California, Colorado, Maryland, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.